Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor

Authors: Sarah L. Carter, Margaret M. Centenera, Wayne D. Tilley, Luke A. Selth, Lisa M. Butler

Published in: BMC Cancer | Issue 1/2016

Login to get access

Excerpt

After publication of the original article [1], the authors requested a change in name format: for the middle name initials, and not the full author names, to be used. This has been changed here and in the original manuscript. …
Literature
1.
Metadata
Title
Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor
Authors
Sarah L. Carter
Margaret M. Centenera
Wayne D. Tilley
Luke A. Selth
Lisa M. Butler
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2215-3

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Chemotherapy for intracranial ependymoma in adults

Research article

New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells

Research article

Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method

Research article

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo

Research article

L1CAM as a prognostic marker in stage I endometrial cancer: a validation study

Study protocol

Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits